Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer

[1]  R. Giugliano,et al.  Novel biomarkers in cardiovascular disease: update 2010. , 2010, American heart journal.

[2]  M. Mimeault,et al.  Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine‐1 in cancer , 2010, Journal of cellular physiology.

[3]  K. Öhrling,et al.  Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer , 2010, Acta oncologica.

[4]  F. Pontén,et al.  The Impact of Tissue Fixatives on Morphology and Antibody-based Protein Profiling in Tissues and Cells , 2010, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[5]  Ulf Landegren,et al.  Sensitive Plasma Protein Analysis by Microparticle-based Proximity Ligation Assays* , 2009, Molecular & Cellular Proteomics.

[6]  E. Rankin,et al.  Regulation of the Histone Demethylase JMJD1A by Hypoxia-Inducible Factor 1α Enhances Hypoxic Gene Expression and Tumor Growth , 2009, Molecular and Cellular Biology.

[7]  F. Pontén,et al.  The Human Protein Atlas—a tool for pathology , 2008, The Journal of pathology.

[8]  Gina Brown,et al.  MRI for detection of extramural vascular invasion in rectal cancer. , 2008, AJR. American journal of roentgenology.

[9]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[10]  Daniel J. Freeman,et al.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. Kerr,et al.  Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study , 2007, The Lancet.

[12]  W. D. Fairlie,et al.  Tumor-induced anorexia and weight loss are mediated by the TGF-β superfamily cytokine MIC-1 , 2007, Nature Medicine.

[13]  Hiroshi Sato,et al.  Cleavage of growth differentiation factor 15 (GDF15) by membrane type 1‐matrix metalloproteinase abrogates GDF15‐mediated suppression of tumor cell growth , 2007, Cancer science.

[14]  R. Labianca,et al.  Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. , 2007, Journal of the National Cancer Institute.

[15]  C. Hill,et al.  Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. , 2006, Cytokine & growth factor reviews.

[16]  G. Hampton,et al.  Measurement of Serum Levels of Macrophage Inhibitory Cytokine 1 Combined with Prostate-Specific Antigen Improves Prostate Cancer Diagnosis , 2006, Clinical Cancer Research.

[17]  Erik K. Malm,et al.  A Human Protein Atlas for Normal and Cancer Tissues Based on Antibody Proteomics* , 2005, Molecular & Cellular Proteomics.

[18]  J. Cubiella,et al.  Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer , 2005, Gut.

[19]  Ulrich Pfeffer,et al.  The Transforming Growth Factor-β Family Members Bone Morphogenetic Protein-2 and Macrophage Inhibitory Cytokine-1 as Mediators of the Antiangiogenic Activity of N-(4-Hydroxyphenyl)Retinamide , 2005, Clinical Cancer Research.

[20]  U. Weidle,et al.  Analysis of differential gene expression in human melanocytic tumour lesions by custom made oligonucleotide arrays , 2005, British Journal of Cancer.

[21]  Charis Eng,et al.  Genetic classification of benign and malignant thyroid follicular neoplasia based on a three-gene combination. , 2005, The Journal of clinical endocrinology and metabolism.

[22]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[23]  R. Houlston,et al.  Systematic review of microsatellite instability and colorectal cancer prognosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  S. Störkel,et al.  Immunohistochemical Detection of EGFR in Paraffin-embedded Tumor Tissues , 2004, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[25]  T. Hickish,et al.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.

[26]  S. Cha,et al.  Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  K. Kinzler,et al.  Serum Macrophage Inhibitory Cytokine 1 as a Marker of Pancreatic and Other Periampullary Cancers , 2004, Clinical Cancer Research.

[28]  Anthony S-Y Leong,et al.  Pitfalls in Diagnostic Immunohistology , 2004, Advances in anatomic pathology.

[29]  K. Kinzler,et al.  MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  J. Welsh,et al.  Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[31]  P. Russell,et al.  Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer , 2003, Journal of surgical oncology.

[32]  N. Shepherd,et al.  Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer , 2002, Gut.

[33]  Erwin G. Van Meir,et al.  Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1 , 2002, Oncogene.

[34]  P J Catalano,et al.  Molecular predictors of survival after adjuvant chemotherapy for colon cancer. , 2001, The New England journal of medicine.

[35]  S. Baek,et al.  Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. , 2001, Molecular pharmacology.

[36]  L. Aaltonen,et al.  Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. , 2000, Gastroenterology.

[37]  K. Guan,et al.  PTGF-β, a type β transforming growth factor (TGF-β) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-β signaling pathway , 2000 .

[38]  K. Badizadegan,et al.  Prognostic factors in stage T3N0 rectal cancer: do all patients require postoperative pelvic irradiation and chemotherapy? , 1999, Diseases of the colon and rectum.

[39]  W. D. Fairlie,et al.  MIC‐1 is a novel TGF‐β superfamily cytokine associated with macrophage activation , 1999, Journal of leukocyte biology.

[40]  A. Senagore,et al.  Can preoperative and postoperative CEA predict survival after colon cancer resection? , 1994, The American surgeon.

[41]  N. Shepherd,et al.  Prognostic factors in colonic cancer , 1989, Histopathology.

[42]  N. Wolmark,et al.  The Prognostic Significance of Preoperative Carcinoembryonic Antigen Levels in Colorectal Cancer: Results from NSABP Clinical Trials , 1984 .

[43]  I. Talbot,et al.  The clinical significance of invasion of veins by rectal cancer , 1980, The British journal of surgery.

[44]  R. Taylor,et al.  CARCINOEMBRYONIC ANTIGEN , 1974 .

[45]  R. G. Hoffman,et al.  Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. , 1978, The New England journal of medicine.

[46]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[47]  M. Lai,et al.  Identification of serum biomarkers for colorectal cancer metastasis using a differential secretome approach. , 2010, Journal of proteome research.

[48]  B. Glimelius,et al.  A systematic overview of chemotherapy effects in colorectal cancer. , 2001, Acta oncologica.

[49]  P. Uribe,et al.  Microsatellite Instability as a Molecular Marker for Very Good Survival in Colorectal Cancer Patients Receiving Adjuvant Chemotherapy , 2001 .

[50]  K. Guan,et al.  PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[51]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.